Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer (NCT02790944) | Clinical Trial Compass
CompletedNot Applicable
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer
United States300 participantsStarted 2016-05-04
Plain-language summary
The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively within 12 weeks of a confirmed diagnosis of pancreatic ductal adenocarcinoma.
Who can participate
Age range18 Years – 89 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female patients between the ages of 18 and 89 years of age.
* Diagnosed within the previous 12 weeks with histologically or cytologically confirmed PDAC Stage I to IV.
* Ability of participant to understand and the willingness to sign a written informed consent document.
* Participant must agree to sample collection and genetic testing using the 32 gene test, CancerNextTM and allow the test result to be part of their medical record.
Exclusion Criteria:
* Diagnosed with intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, pancreatic neuroendocrine tumors or dysplasia without PDAC.
* Diagnosed with PDAC more than 12 weeks before presenting to the clinical site.
* Patients meeting the above enrollment criteria who have had CancerNext performed previously.